Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.476 USD | -0.63% | -19.63% | -76.52% |
May. 14 | Transcript : The Oncology Institute, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Earnings Flash (TOI) TOI MANAGEMENT LLC Reports Q1 Revenue $94.7M, vs. Street Est of $95.2M | MT |
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-76.52% | 35.66M | - | - | |
+20.76% | 83.46B | C+ | ||
-2.68% | 25.66B | C+ | ||
+3.31% | 17.91B | A- | ||
-15.01% | 16.54B | B | ||
+0.30% | 15.43B | A- | ||
+73.56% | 13.46B | C- | ||
+74.54% | 12.78B | C+ | ||
+39.52% | 12.6B | B- | ||
+1.03% | 12.55B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- TOI Stock
- Ratings The Oncology Institute, Inc.